中国实用医药
中國實用醫藥
중국실용의약
China Practical Medical
2015年
31期
6-8
,共3页
脱氧核苷酸%重组人粒细胞集落刺激因子%白细胞减少%化疗
脫氧覈苷痠%重組人粒細胞集落刺激因子%白細胞減少%化療
탈양핵감산%중조인립세포집락자격인자%백세포감소%화료
Deoxynucleotide%Recombinant human granulocyte colony-stimulating factor%Leukopenia%Chemotherapy
目的 观察脱氧核苷酸钠联合重组人粒细胞集落刺激因子治疗胃癌患者化疗所致白细胞减少的疗效.方法 60例中晚期胃癌患者均给予奥沙利铂联合多西他赛化疗, 随机分为治疗组和对照组, 各30例.对照组在化疗期间检测白细胞水平低于正常范围时给予重组人粒细胞集落刺激因子, 治疗组在此基础上加用脱氧核苷酸钠注射液.观察两组治疗效果.结果 停用化疗药3 d后复查血常规, 治疗组白细胞下降例数占6.67%(2/30), 明显少于对照组36.67%(11/30), 差异有统计学意义(P<0.05), 治疗组出现肝功能损伤的几率明显低于对照组, 差异有统计学意义(χ2=4.336,P<0.05), 且出现肝功能损伤程度较轻.治疗组生活质量改善优于对照组(P<0.05).结论 在肿瘤化疗过程中同时加用重组人粒细胞集落刺激因子和脱氧核苷酸钠预防白细胞减少效果比仅使用粒细胞集落刺激因子显著.
目的 觀察脫氧覈苷痠鈉聯閤重組人粒細胞集落刺激因子治療胃癌患者化療所緻白細胞減少的療效.方法 60例中晚期胃癌患者均給予奧沙利鉑聯閤多西他賽化療, 隨機分為治療組和對照組, 各30例.對照組在化療期間檢測白細胞水平低于正常範圍時給予重組人粒細胞集落刺激因子, 治療組在此基礎上加用脫氧覈苷痠鈉註射液.觀察兩組治療效果.結果 停用化療藥3 d後複查血常規, 治療組白細胞下降例數佔6.67%(2/30), 明顯少于對照組36.67%(11/30), 差異有統計學意義(P<0.05), 治療組齣現肝功能損傷的幾率明顯低于對照組, 差異有統計學意義(χ2=4.336,P<0.05), 且齣現肝功能損傷程度較輕.治療組生活質量改善優于對照組(P<0.05).結論 在腫瘤化療過程中同時加用重組人粒細胞集落刺激因子和脫氧覈苷痠鈉預防白細胞減少效果比僅使用粒細胞集落刺激因子顯著.
목적 관찰탈양핵감산납연합중조인립세포집락자격인자치료위암환자화료소치백세포감소적료효.방법 60례중만기위암환자균급여오사리박연합다서타새화료, 수궤분위치료조화대조조, 각30례.대조조재화료기간검측백세포수평저우정상범위시급여중조인립세포집락자격인자, 치료조재차기출상가용탈양핵감산납주사액.관찰량조치료효과.결과 정용화료약3 d후복사혈상규, 치료조백세포하강례수점6.67%(2/30), 명현소우대조조36.67%(11/30), 차이유통계학의의(P<0.05), 치료조출현간공능손상적궤솔명현저우대조조, 차이유통계학의의(χ2=4.336,P<0.05), 차출현간공능손상정도교경.치료조생활질량개선우우대조조(P<0.05).결론 재종류화료과정중동시가용중조인립세포집락자격인자화탈양핵감산납예방백세포감소효과비부사용립세포집락자격인자현저.
Objective To observe curative effect of deoxynucleotide combined with recombinant human granulocyte colony-stimulating factor in treatment of leukopenia after chemotherapy for gastric cancer.Methods A total of 60 moderate and advanced gastric cancer patients receiving oxaliplatin combined with docetaxel for chemotherapy were randomly divided into treatment group and control group, with 30 cases in each group. The control group received recombinant human granulocyte colony-stimulating factor for low leucocyte level during chemotherapy, and the treatment group received additional deoxynucleotide injection. Curative effects of the two groups were observed.Results Blood routine examination was taken after 3 d of chemotherapy withdrawal. The treatment group had much less cases with leucopenia as 6.67% (2/30) than 36.67% (11/30) of the control group, and their difference had statistical significance (P<0.05). Incidence of liver function impairment was obviously lower in the treatment group than in the control group, and their difference had statistical significance (χ2=4.336, P<0.05). The treatment group had slighter severity of liver function impairment, and its improvement of life quality was better than the control group (P<0.05).Conclusion Implement of deoxynucleotide combined with recombinant human granulocyte colony-stimulating factor in chemotherapy can provide more precise effect in preventing leucopenia than single use of recombinant human granulocyte colony-stimulating factor.
